Oxford Nanopore and Day Zero Diagnostics (DZD) announced a collaboration to develop an end-to-end solution for the diagnosis of bloodstream infections, a leading cause of sepsis.
The companies will collaborate to integrate and optimize a diagnostic system for use in clinical settings, such as hospitals, that will provide same-day identification and genomic-based antibiotic susceptibility profiling without the need for blood culture. The companies plan to pursue regulatory approvals, including with the FDA, in the future.
The diagnostic system will combine DZD’s ultra-high enrichment sample preparation technology and its AI-driven Keynome microbial identification and antibiotic susceptibility pipeline with sequencing reads from Oxford Nanopore’s high-throughput, small-format PromethION 2 Solo. The collaboration is targeting a fully automated sample processing and sequencing workflow that fits the needs of clinical hospital labs.
